About Lantheus
Lantheus (NASDAQ:LNTH) is a dynamic player in the healthcare sector, specializing in diagnostic imaging and targeted therapeutics. The company is dedicated to advancing patient care through the development, manufacture, and commercialization of innovative diagnostic imaging agents and products that assist clinicians in diagnosing and treating cardiovascular and other diseases. Currently, Lantheus has a broad portfolio of products that are used by healthcare professionals around the world in medical imaging procedures. With a strong focus on strategic collaborations and research, Lantheus aims to enhance its existing product lineup and explore new therapeutic areas. Their objective is to improve patient outcomes and deliver value to their stakeholders by investing in growth areas and leveraging their expertise in medical imaging and targeted radiopharmaceuticals.
Snapshot
Operations
Products and/or services of Lantheus
- PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer detection.
- DEFINITY, an ultrasound contrast agent improving visualization of the heart.
- piflufolastat F 18, a diagnostic agent for PET imaging in prostate cancer patients.
- TechneLite, a technetium Tc-99m generator for nuclear medicine procedures.
- Zionexa, a portfolio of biomarkers for oncology precision diagnostics.
- AZEDRA, a high-dose radiotherapy for rare neuroendocrine tumors.
Lantheus executive team
- Mr. Robert J. Marshall Jr., CFACFO & Treasurer
- Dr. Jean-Claude Provost M.D.Chief Science Officer
- Mr. Daniel M. NiedzwieckiChief Administrative Officer, General Counsel & Corporate Secretary
- Mr. Brian A. MarkisonStrategic Advisor
- Ms. Amanda M. MorganChief Commercial Officer
- Ms. Mary Anne HeinoInterim CEO & Executive Chairperson
- Ms. Kimberly BrownChief Accounting Officer
- Dr. Ludger Dinkelborg Ph.D.Head of Research & Development
- Ms. Dorothy BarrSenior Vice President of Manufacturing & Technical Operations
- Ms. Lee Anne HoweChief Information Officer